



PHARMA PRESCRIBED .COM

NEWSLETTER · IN CONVERSATION WITH BELMA ALISPAHIC

AI isn't optional

Belma Alispahic — co-founder and Chief Scientific Officer of Analysis Mode — on bringing AI into bioprocess development, and why future-proofing biomanufacturing is now a scientific necessity, not a nice-to-have.

Belma Alispahic works at a less-visible but critical edge of the industry: bioprocess development, the science of actually making biologic medicines efficiently. As co-founder and Chief Scientific Officer of Analysis Mode, she leads SimCell, an AI-powered platform built to accelerate bioprocess efficiency, cut time to market and future-proof pharmaceutical workflows — and she's not shy about the stakes.



AI isn't optional. It's essential for navigating this complexity.

— Belma Alispahic, on Pharma Prescribed

Where the medicine gets made

Bioprocess development rarely makes headlines, but it decides whether a promising biologic can be produced reliably, affordably and at scale. Belma's argument is that the complexity here has outrun manual methods, and that AI is now the only realistic way to keep pace.

Empowering scientists, not replacing them

Her framing, made on stage at the Bioproduction Congress, is pointedly human. This isn't about algorithms for their own sake; it's about giving scientists tools that let them work at the top of their expertise rather than drowning in complexity.

Future-proofing, deliberately

The biopharma landscape only grows more complex, and Belma's case is that building AI into workflows now is how you stay viable later. It's a systems bet on the unglamorous middle of the pipeline — where much of a medicine's real-world feasibility is quietly decided.



Listen to the full episode

Belma Alispahic on Pharma Prescribed — at pharmaprescribed.com
and wherever you get your podcasts.

Belma Alispahic *is the co-founder and Chief Scientific Officer of Analysis Mode, leading the SimCell AI platform for bioprocess development.*